Merck's COVID-19 antiviral pill vs. Pfizer's: What's the same, what's different

Both Merck and Pfizer have recently released data suggesting their COVID-19 antiviral pills are safe and effective ways to treat COVID-19, and if approved, both could be game changers in the fight against the virus.

Merck's antiviral is called molnupiravir. The drugmaker has already filed for emergency use authorization of the drug, saying it cuts the risk of hospitalization or death from COVID-19 by about 50 percent. The FDA's advisory committee is set to meet Nov. 30 to discuss authorizing the drug.

Pfizer's antiviral is called Paxlovid, and the drugmaker said it cuts the risk of hospitalization or death by 89 percent. The company plans to file for emergency use authorization from the FDA as soon as possible.